Skip to main content
SpringerLink
Log in

Monitoring of immunotherapy with cytokines or monoclonal antibodies

  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

Recombinant cytokines and monoclonal antibodies (mAbs) are increasingly used in the treatment of a number of human diseases. Monitoring of the clinical efficacy of these agents requires specific clinical and laboratory measurements. A number of these novel therapies share common side effects, ranging from fever, headache and general malaise to hypotension, the development of edema leading to the vascular leak syndrome, the occurrence of thromboembolic processes and, in severe cases, organ dysfunction. As an example of the pathogenesis of these side effects, recent data are presented which were obtained in patients receiving immunotherapy with high doses of the cytokine interleukin-2 as an anti-cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbink JJ, Nuijens JH, Eerenberg AJM, Huijbregts CCM, Strack van Schijndel RJM, Thijs LG & Hack CE (1991) Quantification of functional and inactivated α2-macroglobulin in sepsis. Thromb. Haemost. 65: 32–39.

    Google Scholar 

  • Akira S, Taga T & Kishimoto T (1993) Interleukin-6 in biology and medicine. Adv. Immunol. 54: 1–78.

    Google Scholar 

  • Baars JW, De Boer JP, Wagstaff J, Roem D, Eerenberg AJM, Nauta J, Pinedo HM & Hack CE (1992a) Interleukine-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br. J. Haematol. 82: 295–301.

    Google Scholar 

  • Baars JW, Hack CE, Wagstaff J, Eerenberg-Belmer AJM, Wolbink GJ, Thijs LG, Strack van Schijndel RJM, Van der Vall HLJA & Pinedo HM (1992b) The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br. J. Cancer 65: 96–101.

    Google Scholar 

  • Baggiolini M, Walz A & Kunkel SL (1989) Neutrophil-activating peptide-1/interleukin 8 a novel cytokine that activates neutrophils. J. Clin. Invest. 84: 1045–1049.

    Google Scholar 

  • Barton BE & Jackson JV (1993) Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model. Infect. Immun. 61: 1496–1499.

    Google Scholar 

  • Bauer KA, Ten Cate H, Barzegar S, Spriggs DR, Sherman ML & Rosenberg RD (1989) Tumor necrosis factor infusions have a procoagulant effect on hemostatic mechanism of humans Blood 74: 165–172.

    Google Scholar 

  • Beatty K, Bieth B & Travis J (1980) Kinetics of association of serine proteinases with native and oxidized α1-proteinase inhibitor and α1-antichymotrypsin. J. Biol. Chem. 255: 3931–3934.

    Google Scholar 

  • Beutler B, Milsark IW & Cerami A (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–871.

    Google Scholar 

  • Bevilacqua MP, Pober JS, Majeau GR, Cotran RS & Gimbrone Jr MA (1984) Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human endothelial cells. J. Exp. Med. 160: 618–623.

    Google Scholar 

  • Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS & Gimbrone Jr MA (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukinl. Proc. Natl. Acad. Sci. USA 83: 4533–4537.

    Google Scholar 

  • Bizios R, Lai L, Fenton JW & Malik AB (1986) Thrombin-induced chemotaxis and aggregation of neutrophils. J. Cell Physiol. 128: 485–490.

    Google Scholar 

  • Bjork J, Hugli TE & Smedegard G (1985) Microvascular effects of anaphylatoxins C3a and C5a. J. Immunol 134: 1115–1119.

    Google Scholar 

  • Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F & Peschle C (1990) Adoptive immunotherapy of human cancer: The cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res. 50: 5795–5800.

    Google Scholar 

  • Bone RC (1991) The pathogenesis of sepsis. Ann. Intern. Med. 115: 457–469.

    Google Scholar 

  • Brower MS & Harpel PC (1982) Proteolytic cleavage and inactivation of α2-plasmin inhibitor and C1-inactivator by human polymorphonuclear leucocyte elastase. J. Biol. Chem. 257: 9849–9854.

    Google Scholar 

  • Bucklin SE, Silverstein R & Morrison DC (1993) An interleukin-6-induced acute-phase response does not confer protection against lipopolysaccharide lethality. Infect. Immun. 61: 3184–3189.

    Google Scholar 

  • Butler LD, Layman NK, Cain RL, Riedl PE, Mohler KM, Bobbitt JL, Belagajie R, Sharp J & Bendele AM (1989) Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention. Clin. Immunol. Immunopathol. 53: 400–421.

    Google Scholar 

  • Camussi G, Tetta C & Baglione C (1990) The role of Platelet-activating factor in inflammation. Clin. Immunol. Immunopathol. 57: 331–338.

    Google Scholar 

  • Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, Van der Meer JWM, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF & Dinarello CA (1990) Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161: 79–84.

    Google Scholar 

  • Carlos TM & Harlan JM (1990) Membrane proteins involved in phagocyte adherence to endothelium. Immunol. Rev. 114: 6–28.

    Google Scholar 

  • Carrell RW & Owen MC (1985) Plakalbumin, α1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 317: 730–732.

    Google Scholar 

  • Carrell RW, Christey PB & Boswell DR (1987) Serpins: antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from amino acid sequences. In Verstraete M, Vermylen J, Lijnen R & Arnout J (eds.) Thrombosis and Haemostasis (pp. 1–15) Leuven University Press, Leuven.

    Google Scholar 

  • Cerami A & Beutler B (1988) The role of cachectin/TNF in endotoxic shock and cachexia. Immunol. Today 9: 28–31.

    Google Scholar 

  • Clark RA, Stone PJ, El Hag A, Calore JD & Franzblau C (1981) Myeloperoxidase-catalyzed inactivation of α1-protease inhibitor by human neutrophils. J. Biol. Chem. 256: 3348–3353.

    Google Scholar 

  • Cochrane CG & Griffin JH (1982) The biochemistry and pathophysiology of the contact system of plasma. Adv. Immunol. 33: 241–304.

    Google Scholar 

  • Colman RW (1984) Surface-mediated defense reactions. The plasma contact activation system. J. Clin. Invest. 73: 1249–1253.

    Google Scholar 

  • Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, Scott CF, De Agostini A, Burger D & Schapira M (1985) Effect of cleavage of the heavy chain of human plasma kallikrein and its functional properites. Blood 65: 311–318.

    Google Scholar 

  • Colman RW & Schmaier AH (1986) The contact activation system: biochemistry and interactions of these surface-mediated defense reactions. Crit-Rev-Oncol-Hematol. 5: 57–85.

    Google Scholar 

  • Craddock PR, Hammerschmidt DE, Moldow CF, Yamada O & Jacob HS (1977) Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination. Seminars in Hematology 16: 140–147.

    Google Scholar 

  • Crowl RM, Stoller JT, Conroy RR & Stoner CR (1991) Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 226: 2647–2651.

    Google Scholar 

  • Damle NK, Doyle LV, Bender JR & Bradley EC (1987) Interleukin-2 activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J. Immunol. 138: 1779–1785.

    Google Scholar 

  • Damle NK & Doyle LV (1989) IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leakage syndrome. J. Immunol. 142: 2660–2669.

    Google Scholar 

  • De Groote MA, Martin MA, Densen P, Pfaller MA & Wenzel RP (1989) Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 262: 249–251.

    Google Scholar 

  • Desrochers PE & Weiss SJ (1938) Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase. J. Clin. Invest. 81: 1646–1650.

    Google Scholar 

  • Dinarello CA (1988) Biology of interleukin 1. FASEB J 2: 108–115.

    Google Scholar 

  • Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627–1652.

    Google Scholar 

  • Dustin ML & Springer TA (1988) Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J. Cell. Biol. 107: 321–331.

    Google Scholar 

  • Fey GH & Gauldie J (1990) The acute phase response of the liver in inflammation. In: Popper H & Schaffner F (eds.) Progress in liver disease, Vol 9 (pp. 89–116) W.B. Saunders Company, Philidelphia.

    Google Scholar 

  • Fischer E, Marano MA, Barber AE, Hudson A, Lee K, Rock CS, Hawes AS, Thompson RC, Hayes TJ, Anderson TD, Benjamin WR, Lowry SF & Moldawer LL (1991) Comparison between effects of interleukin-1α administration and sublethal endotoxemia in primates. Am. J. Physiol 261: R442-R452.

    Google Scholar 

  • Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF & Cerami A (1989) Antibodies to cachectin/turnor necrosis factor reduce interleukin 1β and interleukin 6 appea ance during lethal bacteremia. J. Exp. Med. 170: 1627–1633.

    Google Scholar 

  • Gamble JR, Harlan JM & Klebanoff SJ (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl Acad. Sci. USA 82: 8667–8671.

    Google Scholar 

  • Gauldie I, Richards C, Harnish D, Lansdorp PM & Baumann H (1987) Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cell. Proc. Natl Acad. Sci. USA 84: 7251–7255.

    Google Scholar 

  • Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME Thomas JX, Fisher SG & Fisher RI (1988) The hemodynamic effects of treatment with interleukin-2 and lymphokine activated killer cells. Ann. Intern. Med. 109: 953–958.

    Google Scholar 

  • Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T & Heinrich PC (1988) Induction of rat acute-phase proteins by interleukin 6in vivo. Eur. J. Immunol. 18: 717–721.

    Google Scholar 

  • Gemlo BT (1988) Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokineactivated killer cells. Cancer Res. 48: 5864–5867.

    Google Scholar 

  • Girardin E, Grau GE, Dayer J-M, Roux-Lambard P, the J5 Study Group & Lambert P-H (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infections purpura. N. Engl. J. Med. 319: 397–400.

    Google Scholar 

  • Goldstein IM, Roos D, Kaplan HB & Weissman G (1975) Complement and immunoglobulines stimulate superoxide production by human leucocytes indepently of phagocytosis. J. Clin. Invest. 56: 1155–1163.

    Google Scholar 

  • Goldstein IM (1988) Complement: Biological Active Product. In: Gallin JI, Goldstein IM & Snyderman R (eds.) Inflammation: Basic Principles and Clinical Correlates (pp. 55–74) Raven Press, Ltd., New York.

    Google Scholar 

  • Grossman N & Leive L (1984) Complement activation via the alternative pathway by purified Salmonella lipopolysaccharide is affected by its structure but not its O-antigen length. J. Immunol. 132: 376–385.

    Google Scholar 

  • Hack CE, De Groot ER, Felt-Bersma RJF, Nuijens JH, Van Schijndel RJMS, Eerenberg-Belmer AJM, Thijs LG & Aarden LA (1989) Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704–1710.

    Google Scholar 

  • Hack CE, Nuijens JH, Strack van Schijndel RJM, Abbink JJ, Eerenberg AJM & Thijs LG (1990) A model for the interplay of inflammatory mediators in sepsis: a study in 48 patients. Intensive Care Med 16: 187–191.

    Google Scholar 

  • Hack CE, Wagstaff J, Strack van Schijndel RJM, Eerenberg AJM, Pinedo HM, Thijs LG & Nuijens JH (1991) Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock. Thromb. Haemost 65: 497–503.

    Google Scholar 

  • Hack CE, Hart M, Strack van Schijndel RJM, Eerenberg AJM, Nuijens JH, Thijs LG & Aarden LA (1992) Interleukin-8 in sepsis: Relation to shock and inflammatory mediators. Infect. Immun. 60: 2853–2842.

    Google Scholar 

  • Hamilton KK, Hattori R, Esmon CT & Sims PJ (1990) Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J. Biol. Chem. 265: 3809–3814.

    Google Scholar 

  • Hammerschmidt DE, Hudson LD, Weaver LJ, Craddock PR & Jacob HS (1980) Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome: pathophysiological relevance and possible prognostic value. Lancet I: 947–949.

    Google Scholar 

  • Harlan JM (1985) Leukocyte-endothelial interactions. Blood 65: 513–525.

    Google Scholar 

  • Hechtman DH, Cybulsky MI, Fuchs HJ, Baker JB & Gimbrone Jr MA (1991) Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J. Immunol. 147: 883–892.

    Google Scholar 

  • Heinrich PC, Castell JV & Andus T (1990) Interleukin-6 and the acute phase response. Biochem. J. 269, Suppl.: 51–66.

    Google Scholar 

  • Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino Jr MA, Cerami A, Shires GT & Lowry SF (1988) Cytokine appearance in human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet 166: 147–153.

    Google Scholar 

  • Hesselvik JF, Blombäck M, Brodin B & Maller R (1989) Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit. Care Med. 17: 724–733.

    Google Scholar 

  • Hibbs Jr JB, Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, Ward JH, Menlove RL, McMurry MP, Kushner JP & Samlowski WE (1992) Evidence for cytokine-inducible nitric oxide synthesis from L-Arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. 89: 867–877.

    Google Scholar 

  • Hugli TE (1984) Structure and function of the anaphylatoxins. Springer Semin. Immunopathol. 7: 193–219.

    Google Scholar 

  • Jablons DM, Mulé JJ, McIntosh JK, Sehgal PB, May LT, Huang CM, Rosenberg SA & Lotze MT (1989) IL-6/IFN-β-2 as a circulating hormone. Induction by cytokine administration in humans. J. Immunol. 142: 1542–1547.

    Google Scholar 

  • Jiang H, Robey FA & Gewurz H (1992) Localization of sites through which C-reactive protein binds and activates complement to residues 14–26 and 76–92 of the human C1q A chain. J. Exp. Med. 175: 1373–1379.

    Google Scholar 

  • Johnson D & Travis J (1979) The oxidative inactivation of human α-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J. Biol. Chem. 254: 4022–4026.

    Google Scholar 

  • Kalter ES, Van Dijk WC, Timmermans A, Verhoef J & Bouma BN (1983) Activation of purified human plasma prekallikrein triggered by cell wall fraction; ofEscherichia coli andStaphylococcus aureus. J. Infect. Dis. 148: 692–697.

    Google Scholar 

  • Kaplan AP, Kay AB & Austen KF (1972) A prealbumin activator pf prekallikrein. II. Appearance of chemotactic activity for neutrophils by the conversion of human prekallikrein to kallikrein. J. Exp. Med.. 135: 81–97.

    Google Scholar 

  • Kaplan AP (1985) The intrinsic coagulation, fibrinolytic and kininforming pathways of man. In: Kelley WN, Harris ED, Ruddy S & Sledge CB (eds.) Textbook of Rheumatology (pp. 95–114) WB Saunders, Philadelphia.

    Google Scholar 

  • Kaplan AP & Silverberg M (1987) The coagulation-kinin pathway of human plasma. Blood 70: 1–15.

    Google Scholar 

  • Kasid A, Director EP & Rosenberg SA (1989) Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J. Immunol. 143: 736–739.

    Google Scholar 

  • Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R & Lodato RF (1990)N G-Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA 87: 3629–3632.

    Google Scholar 

  • Kishimoto T, Akira S & Taga T (1992) Interleukin-6 and its receptor: a paradigm for cytokines. Sciences 258: 593–597.

    Google Scholar 

  • Kohase M, Henriksen-Destefano D, May LT, Vilçek J & Sehgal PB (1986) Induction of β2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell 45: 659–666.

    Google Scholar 

  • Kozin F & Cochrane CG (1988) The contact activation system of plasma: Biochemistry and pathophysiology. In: Gallin JI, Goldstein IM & Snyderman R (eds.) Inflammation: Basic Principles and Clinical Correlates (pp. 101–120) Raven Press Ltd, New York.

    Google Scholar 

  • Kramps JA, Van Twisk C & Dijkman JH (1987) Oxidative inactivation of antileukoprotease by triggered polymorphonuclear leukocytes. Am. Rev. Respir. Dis. 135: 290 (Abstract).

    Google Scholar 

  • Kress LF (1986) Inactivation of human plasma serine proteinase inhibitors (serpins) by limited proteolysis of the reactive site loop with snake venom and bacterial metalloproteinases. J. Cell Bioch. 32: 51–58.

    Google Scholar 

  • Kushner I & Kaplan MH (1961) Studies of acute-phase protein. I. An immuno-histochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions. J. Exp. Med. 114: 961–974.

    Google Scholar 

  • Kushner I, Rakita L & Kaplan MH (1993) Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J. Clin. Invest. 42: 286–292.

    Google Scholar 

  • Larrick JW, Graham D, Toy K, Lin LS, Senyk G & Fendly BM (1987) Recombinant tumor necrosis factor activation of human granulocytes. Blood 69: 640–644

    Google Scholar 

  • Larrick JW & Wright SC (1990) Cytotoxic mechanism of tumor necrosis factor-α. FASEB J. 4: 3215–3223.

    Google Scholar 

  • Le J & Vilçek J (1987) Biology of disease; tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab. Invest. 56: 234–248.

    Google Scholar 

  • Leonard EJ, Yoshimura T, Tanaka S & Raffeld M (1991) Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1. J. Invest. Dermatol. 96: 690–694.

    Google Scholar 

  • Leroux-Roels G & Oftner F (1990) Tumor necrosis factor in sepsis. JAMA 263: 1494–1495.

    Google Scholar 

  • Levin EG & Santell L (1987) Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J. Cell Biol. 105: 2543–2549.

    Google Scholar 

  • Lundberg C, Marcheau F & Hugli TE (1987) C5a-induced hemodynamic and hematologic changes in the rabbit. Am. J. Pathol. 128: 471–483.

    Google Scholar 

  • Malik AB (1986) Thrombin-induced endothelial injury. Semin. Thromb. Hemost. 12: 184–196.

    Google Scholar 

  • Mantovani A & Dejana E (1989) Cytokines as communication signals between leukocytes and endothelial cells. Immunol. Today 10: 370–375.

    Google Scholar 

  • Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA & Murray JF (1990) Plasma tumor necrosis factor in patients with septic shock: Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am. Rev. Respir. Dis. 141: 94–97.

    Google Scholar 

  • Marks RM, Todd III RF & Ward PA (1989) Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 339: 314–317.

    Google Scholar 

  • Martin S, Maruta K, Burkart V, Gillis S & Kolb H (1988) IL-1 and IFN-gamma increase vascular permeability. Immunology 64: 301–305.

    Google Scholar 

  • Mathison JC, Wolfson E & Ulevitch RJ (1988) Participation of tumor necrosis factor in the mediation of Gram negative bacterial lipopolysccharide-induced injury in rabbits. J. Clin. Invest. 81: 1925–1937.

    Google Scholar 

  • McCabe WR, Treadwell TL & De Maria Jr A (1983) Pathophysiology of bacteremia. Am. J. Med. 75: 7–18.

    Google Scholar 

  • McEver RP (1991) Selectins: novel receptors that mediate leukocyte adhesion during inflammation. Thromb. Haemost. 65: 223–228.

    Google Scholar 

  • Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM & Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318: 1481–1486.

    Google Scholar 

  • Mier JW, Vachino G, Van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR & Dinarello CA (1988) Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol. 8: 426–436.

    Google Scholar 

  • Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Brandon EP, Laird W & Atkins MB (1990) Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prvention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 10: 1933–1940.

    Google Scholar 

  • Moalli R, Doyle JM, Tahhan HR, Hasan FM, Braman SS & Saldeen T (1989) Fibrinolysis in critically ill patients. Am. Rev. Respir. Dis. 140: 287–293.

    Google Scholar 

  • Mold C, Du Clos TW, Nakayama S, Edwards KM & Gewurz H (1982) C-reactive protein reactivity with complement and effects on phagocytosis. Ann. N.Y. Acad. Sci. 389: 251–259.

    Google Scholar 

  • Morrison DC & Cochrane CG (1974) Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J. Exp. Med. 140: 797–811.

    Google Scholar 

  • Morrison DC & Kline LF (1977) Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J. Immunol. 118: 362–368.

    Google Scholar 

  • Morrison DC & Ulevitch RJ (1978) The effects of bacterial endotoxins on host mediation systems. Am. J. Pathol. 93: 527–617.

    Google Scholar 

  • Müller-Eberhard HJ (1988) Complement: chemistry and pathways. In: Gallin JI, Goldstein IM & Snyderman R (eds.) Inflammation: Basic Principles and Clinical Correlates (pp. 21–53) Raven Press, Ltd., New York.

    Google Scholar 

  • Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ & Parrillo JE (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. 169: 823–832.

    Google Scholar 

  • Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L & Stern D (1986) Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163: 1363–1375.

    Google Scholar 

  • Nawroth PP & Stern DM (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163: 740–745.

    Google Scholar 

  • Nijsten MWN, De Groot ER, Ten Duis HJ, Klasen HJ, Hack CE & Aarden LA (1987a) Serum levels of interleukin-6 and acute phase responses. Lancet II: 921.

    Google Scholar 

  • Nijsten MWN, De Groot ER, Ten Duis HJ, Klasen HJ, Hack CE & Aarden LA (1987b) Serum levels of interleukin-6 and acute phase responses. Lancet II: 921.

    Google Scholar 

  • Nijsten MWN, Hack CE, Helle M, Ten Duis HJ, Klasen HJ & Aarden LA (1991) Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery 109: 761–767.

    Google Scholar 

  • Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM, Schreuder WO, Felt-Bersma RJF, Abbink JJ, Thijs LG & Hack CE (1989) Proteolytic inactivation of plasma C1-Inhibitor in sepsis. J. Clin. Invest. 84: 443–450.

    Google Scholar 

  • Ogilvie AC, Baars JW, Eerenberg AJM, Hack CE, Pinedo HM, Thijs LG & Wagstaff J (1994) A pilot study to evaluate the effects of C1-esterase inhibitor on the toxicity of high dose interleukin-2. Br. J. Cancer (in press).

  • Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, Shelhamer JH & Parillo JE (1983) Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94: 750–754.

    Google Scholar 

  • Okusawa S, Gelfland JA, Ikejima T, Connolly RJ & Dinarello CA (1988) Interleukin 1 induces a shock-like state in rabbits. J. Clin. Invest. 81: 1162–1172.

    Google Scholar 

  • Osterud B, Olsen JO & Benjaminsen AW (1984) The role of complement in the induction of thromboplasmin synthesis. Haemostasis 14: 386–392.

    Google Scholar 

  • Piguet PF, Grau GE & Vassalli P (1990) Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am. J. Pathol. 136: 103–110.

    Google Scholar 

  • Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr FB & Colman RW (1993) The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia:In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J. Clin. Invest. 91: 61–68.

    Google Scholar 

  • Pober JS & Cotran RS (1991) What can be learned from the expression of endothelial adhesion molecules in tissues? Lab. Invest. 64: 301–305.

    Google Scholar 

  • Pohlman TH, Stanness KA, Beatty PG, Ochs HD & Harlan JM (1986) An endothelial cell surface factor(s) inducedin vitro by lipopolysaccharide, interleukin-1 and tumor necrosis factor-α increases neutrophil adherence by a CDw 18-dependent mechanism. J. Immunol. 136: 4548–4553.

    Google Scholar 

  • Pratt CW, Tobin RB & Church FC (1990) Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. J. Biol. Chem. 265: 6092–6097.

    Google Scholar 

  • Preiser JC, Schmartz D, Van der Linden P, Content J, Van den Bussche P, Buurman W, Sebald W, Dupont E, Pinsky MR, & Vincent JL (1991) Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine 3: 1–4.

    Google Scholar 

  • Prescott SM, Zimmermann GA & McIntyre TM (1990) Platelet-activating factor. J. Biol. Chem. 29: 17381–17384.

    Google Scholar 

  • Reddy VY, Pizzo SV & Weiss SJ (1989) Functional inactivation and structural disruption of human α2-macroglobulin by neutrophils and eosinophils. J. Biol. Chem. 264: 13801–13809.

    Google Scholar 

  • Remick DG, Kunkel RG, Larrick JW & Kunkel SL (1987) Acutein vivo effects of human recombinant tumor necrosis factor. Lab. Invest. 56: 583–590.

    Google Scholar 

  • Remick DG, Strieter RM, Eskandari MK, Nguyen DT, Genord MA, Raiford CL & Kunkel SL (1990) Role of tumor necrosis factoralpha in lipopolysaccharide-induced pathologic alteractions. Am. J. Pathol. 136: 49–60.

    Google Scholar 

  • Robaye B, Mosselmans R, Fiers W, Dumont JE & Galand P (1991) Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cellsin vitro. Am. J. Pathol. 138: 447–453.

    Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Marston Lineman W, Robertson CN, Lee RA, Rubin JT, Seipp C, Simpson CG & White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316: 889–897.

    Google Scholar 

  • Rosenberg SA, Lotze MT & Mule JJ (1988) New approaches to the immunotherapy of cancer using interleukin-2. Ann. Intern. Med. 108: 853–864.

    Google Scholar 

  • Rosenstein M, Ettinghausen SE & Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J. Immunol. 137: 1735–1742.

    Google Scholar 

  • Ruoslahti E (1991) Integrins. J. Clin. Invest. 87: 1–5.

    Google Scholar 

  • Ryffel B, Car BD, Woerly G, Weber M, DiPadova F, Kammuller M, Klug S, Neubert R & Neubert D (1994) Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acutephase protein synthesis in a small primate — The marmoset. Blood 83: 2093–2102.

    Google Scholar 

  • Sacks T, Moldow CF, Craddock PR, Bowers TK & Jacob HS (1978) Oxygen radical mediate endothelial cell damage by complement-stimulated granulocytes. J. Clin. Invest. 61: 1161–1167.

    Google Scholar 

  • Sagone AL, Husney RM, Triozzi PL & Rinehart J (1991) Interleukin-2 therapy enhances salicylate oxidation of blood granulocytes. Blood 78: 2931–2936.

    Google Scholar 

  • Saito H (1987) Contact factors in health and disease. Thromb. Haemost. 13: 36–49.

    Google Scholar 

  • Schapira M, Despland E, Scott CF, Boxer LA & Colman RW (1982) Purified human plasma kallikrein aggregates human blood neutrophils. J. Clin. Invest. 69: 1199–1202.

    Google Scholar 

  • Schapira M, Henry J, Wachtfogel YT et al. (1983) A role for plasma kallikrein in rheumatoid arthritis. Clin. Res. 31: 454A.

    Google Scholar 

  • Schleimer RP & Rutledge BK (1986) Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol esters. J. Immunol. 136: 649–654.

    Google Scholar 

  • Schuger L, Varani J, Marks RM, Kunkel SL, Johnson KJ & Ward PA (1989) Cytotoxicity of tumor necrosis factor-alpha for human umbilical vein endothelial cells. Lab. Invest. 61: 62–68.

    Google Scholar 

  • Smedly LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB, Henson PM & Worthen GS (1986) Neutrophilmediated injury to endothelia cells: enhancement by endotoxin and essential role of neutrophil elastase. J. Clin. Invest. 77: 1233–1242.

    Google Scholar 

  • Smith D, Gilbert M & Owen WG (1985) Tissue plasminogen activator releasein vivo in response to vasoactive agents. Blood 66: 835–839.

    Google Scholar 

  • Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA & Raffin TA (1986) Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77: 1812–1816.

    Google Scholar 

  • Strieter RM, Koch AE, Antony VB, Fick Jr RB, Standiford TJ & Kunkel SL (1994) The mmunopathology of chemotactic cytokines: The role of interleukin-8 and monocyte chemoattractant protein-1. J. Lab. Clin. Med. 123: 183–197.

    Google Scholar 

  • Suffredini AF, Harpel PC & Parillo JE (1989) Promotion and subsequent inhibition of plasminogen activator after administation of intravenous endotoxin to normal subjects. N. Engl. J. Med. 18: 1165–1171

    Google Scholar 

  • Taga T (1992) IL6 signalling through IL6 receptor and receptorassociated signal transducer, gp130. Res. Immunol. 143: 737–739.

    Google Scholar 

  • Tahamont MV & Malik AB (1983) Granulocytes mediate the increase in pulmonary vascular permeability after thrombin embolism. J. Appl. Physiol. 54: 1489–1495.

    Google Scholar 

  • Taylor Jr FB, Emerson Jr TE, Jordan R, Chang AK & Blick KE (1988) Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ. Shock 26: 227–235.

    Google Scholar 

  • Teitel JM & Rosenberg RD (1983) Protection of factor Xa from neutralization by the heparin-anti-thrombin complex. J. Clin. Invest. 71: 1383–1391.

    Google Scholar 

  • Thijs LG, Hack CE, Strack van Schijndel RJM, Nuijens JH, Wolbink GJ, Eerenberg-Belmer AJM, Vall van der H & Wagstaff J (1989) Complement activation and high-dose of interleukin-2. Lancet 2: 395.

    Google Scholar 

  • Thijs LG, Hack CE, Strack van Schijndel RJM, Nuijens JH, Wolbink GJ, Eerenberg-Berenberg-Belmer AJM, Vall van der H & Wagstaff J (1990) Activation of the complement system during immunotherapy with recombinant Interleukin-2: Relation to the development of side effects. J. Immunol. 144: 2419–2424.

    Google Scholar 

  • Tilg H, Shapiro L, Atkins MB, Dinarello CA & Mier JW (1993a) Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of itsin vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J. Immunol. 151: 3299–3307.

    Google Scholar 

  • Tilg H, Vannier E, Vachino G, Dinarello CA & Mier JW (1993b) Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1-beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178: 1629–1636.

    Google Scholar 

  • Tilg H, Trehu E, Atkins MB, Dinarello CA & Mier JW (1994) Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113–118.

    Google Scholar 

  • Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri R, Fahey III TJ, Zentella A, Albert JD, Shires GT & Cerami A (1986) Shock and tissue injury induced by human recombinant cachectin. Science 234: 470–474.

    Google Scholar 

  • Tracey KJ, Fong Y, Hesse DG, Monogue KR, Lee AT, Kuo GC, Lowry SF & Cerami A (1987a) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal lethal bacteraemia. Nature 330: 662–664.

    Google Scholar 

  • Tracey KJ, Lowry SF, Fahey III TJ, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KB, Calvano SE, Wei H, Cerami A & Shires GT (1987b) Cachectin tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 164: 415–422.

    Google Scholar 

  • Tracey KJ, Vlassara H & Cerami A (1989) Cachectin/tumour necrosis factor. Lancet III: 1122–1125.

    Google Scholar 

  • Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P & Mier JW (1991) Complement activation in cancer patients under-going immunotherapy with interleukin-2 (IL-2): Binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 78: 2505–2513.

    Google Scholar 

  • Van Damme J, Opdenakker G, Simpson RJ, Rubira MR, Cayphas S, Vink A, Billiau A & Van Snick J (1987) Identification of the human 26kDa protein, interferon β2 (IFNβ2) as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J. Exp. Med. 165: 914–919.

    Google Scholar 

  • Van der Meer JWM, Helle M & Aarden LA (1989) Comparison of the effects of recombinant interleukin-6 and recombinant interleukin-1 on nonspecific resistance to infection. Eur. J. Immunol. 19: 413–416.

    Google Scholar 

  • Van der Poll T, Büller HR, Ten Cate H, Wortel CH, Bauer KA, Van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD & Ten Cate JW (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 322: 1622–1626.

    Google Scholar 

  • Van der Poll T, Levi M, Buller HR, Van Deventer SJH, De Boer JP, Hack CE & Ten Cate JW (1991) Fibrinolytic response to tumor necrosis factor in healthy subjects. J. Exp. Med. 174: 729–732.

    Google Scholar 

  • Van Deventer SJH, Büller HR, Ten Cate JW, Aarden LA, Hack CE & Sturk A (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76: 2520–2526.

    Google Scholar 

  • Van Hinsbergh VWM, Kooistra T, Van den Berg EA, Princen HMG, Fiers W & Emeis JJ (1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cellsin vitro and ratsin vivo. Blood 72: 1467–1473.

    Google Scholar 

  • Vane JR, Anggård EE & Botting RM (1990) Regulatory functions of the vascular endothelium. N. Engl. J. Med. 323: 27–36.

    Google Scholar 

  • Varani J, Ginsburg I, Schuger L, Gibbs DF, Bromberg J, Johnson KJ, Ryan US & Ward PA (1989) Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am. J. Pathol. 135: 435–438.

    Google Scholar 

  • Vissers MCM, George PM, Bathurst IC, Brennan SO & Winterbourn CC (1988) Cleavage and inactivation of α1-antitrypsin by metalloproteinases released from neutrophils. J. Clin. Invest. 82: 706–711.

    Google Scholar 

  • Vogt W (1986) Anaphylatoxins: possible roles in disease. Complement 3: 177–188.

    Google Scholar 

  • Voss R, Matthias FR, Borkowski G & Reitz D (1990) Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br. J. Haematol. 75: 99–105.

    Google Scholar 

  • Waage A, Brandtzaeg P, Halstensen A, Kierulf P & Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169: 333–338.

    Google Scholar 

  • Wachtfogel YT, Kucich U, James HV, Scott CF, Shapira M, Zimmerman M, Cohen AB & Colman RW (1983) Human plasma kallikrein releases neutrophil elastase during blood coagulation. J. Clin. Invest. 72: 1672–1677.

    Google Scholar 

  • Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Eeinbaum G, Schapira M & Colman RW (1986) Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 67: 1731–1737.

    Google Scholar 

  • Walther Z, May LT & Sehgal PB (1988) Transcriptional regulation of the interferon-β2/B-cell differentiation factor BSF-2/hepatocyte stimulating factor gene in human fibroblasts by other cytokines. J. Immunol. 140: 974–977.

    Google Scholar 

  • Ward PA (1991) Mechanisms of endothelial cell injury. J. Lab. Clin. Med. 118: 421–426.

    Google Scholar 

  • Wardlaw A (1990) Leucocyte adhesion to endothelium. Clin. Exp. All. 20: 619–626.

    Google Scholar 

  • Weiss SJ (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320: 365–376.

    Google Scholar 

  • Weissmann G (1989) The role of neutrophils in vascular injury: a summary of signal transduction mechanisms in cell/cell interactions. Springer Semin. Immunopathol. 11: 235–258.

    Google Scholar 

  • Weitz JI, Hudoba M, Massel D, Maraganore J & Hirsh J (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86: 385–391.

    Google Scholar 

  • Wolbink GJ, Bollen J, Baars JW, Ten Berge RJM, Swaak AJG, Paardekooper J & Hack CE (1993) Application of a monoclonal antibody gainst a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods 163: 67–76.

    Google Scholar 

  • Wong GG & Clark SC (1988) Multiple actions of interleukin 6 within a cytokine network. Immunol. Today 9: 137–139.

    Google Scholar 

  • Yamada O, Moldow CF, Sacks T, Craddock PR, Boogaerts MA & Jacob HS (1981) Deleterious effects of endotoxin on cultured endothelial cells: anin vitro model of vascular injury. Inflammation 5: 115–126.

    Google Scholar 

  • Yamamoto T & Cochrane CG (1981) Guinae pig Hageman factor as a vascular permeability enhancement factor. Am. J. Pathol. 105: 164–175.

    Google Scholar 

  • Yancey KB (1988) Biological properties of human C5a: selectedin vitro studies. Clin. Exp. Immunol. 71: 207–210.

    Google Scholar 

  • Yuo A, Fey G, Kitagawa S, Ohsaka A, Ohta M, Miyazao K, Okabe T, Urabe A, Saito M & Takaku F (1989) Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood 74: 2144–2149.

    Google Scholar 

  • Zaslow MC, Clark RA, Stone PJ, Calore JD, Snider GL & Franzblau C (1983) Human neutrophil elastase does not bind to alphalprotease inhibitor that has been exposed to activated human neutrophils. Am. Rev. Respir. Dis. 128: 434–439.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Laboratory for Experimental and Clinical Immunology, University of Amsterdam, P.O. Box 9406, 1006 AK, Amsterdam, The Netherlands

    C. Erik Hack

  2. Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands

    C. Erik Hack

Authors
  1. C. Erik Hack
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erik Hack, C. Monitoring of immunotherapy with cytokines or monoclonal antibodies. Cytotechnology 18, 93–106 (1995). https://doi.org/10.1007/BF00744324

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00744324

Key words

Search

Navigation